Johnson & Johnson Chief Executive Joaquin Duato said on Tuesday that tariffs on pharmaceuticals can create supply chain ...

Johnson & Johnson stock slipped Tuesday, even after the company reported first-quarter earnings that surpassed expectations ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

Johnson & Johnson is increasing its dividend for the 63rd consecutive year. This further cements the healthcare giant's ...

Johnson & Johnson’s Q1 2025 earnings reveal growth in sales and EPS, boosted by MedTech and Pharma. Click for my updated look at JNJ and its most recent news.

Health care giant Johnson & Johnson expects about $400 million in tariff-related costs this year. The costs will be felt ...

Cheeseheads and cheesecakes join the punchlines and headlines, and an enthusiastic audience gets a mild scolding for slipping ...